Affiliation
Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester, UK.Issue Date
2011-12
Metadata
Show full item recordAbstract
Recent recognition of the high prevalence of neuroendocrine tumors in combination with a sustained failure to improve outcomes for patients with advanced disease has elevated their priority for research and drug development. Sunitinib (SU11248, Sutent; Pfizer Inc. NY, USA) potently inhibits multiple-receptor tyrosine kinases, resulting in antiangiogenic effects. A growing body of evidence indicates angiogenesis is a clinically relevant therapeutic target in pancreatic neuroendocrine tumors, culminating in a Phase III randomized study of sunitinib in patients with advanced progressive pancreatic neuroendocrine tumors. Sunitinib has recently gained regulatory approval as a single agent in this setting, and future studies will investigate most appropriate patient selection, and sequencing and combination with other targeted and cytotoxic agents. Here, we discuss in detail the molecular properties, clinical efficacy and safety of sunitinib in the context of pancreatic neuroendocrine tumors.Citation
Sunitinib for advanced pancreatic neuroendocrine tumors. 2011, 11 (12):1817-27 Expert Rev Anticancer TherJournal
Expert Review of Anticancer TherapyDOI
10.1586/era.11.171PubMed ID
22117148Type
ArticleLanguage
enISSN
1744-8328ae974a485f413a2113503eed53cd6c53
10.1586/era.11.171
Scopus Count
Related articles
- Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors.
- Authors: Bisht S, Feldmann G, Brossart P
- Issue date: 2013 Jun
- Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States.
- Authors: Casciano R, Chulikavit M, Perrin A, Liu Z, Wang X, Garrison LP
- Issue date: 2012
- Targeted therapies: Good news for advanced-stage pancreatic neuroendocrine tumors.
- Authors: Spiegel AM, Libutti SK
- Issue date: 2011 May
- Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
- Authors: Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P
- Issue date: 2011 Feb 10
- Sunitinib in pancreatic neuroendocrine tumors.
- Authors: Raymond E, Hammel P, Dreyer C, Maatescu C, Hentic O, Ruszniewski P, Faivre S
- Issue date: 2012 Jun